{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 41,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a biological diagram to illustrate EGFR mutations in GBM.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/30",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Nearly 60% of patients have an EGFR alteration of which 85% have an EGFR amplification",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee4d0fe-5db2-45f5-bd3d-0634029c626b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1 SEER Database (US) and ECIS Database (EU); AACR Genie. ORR: objective response rate; GBM: glioblastoma; CNS: central nervous system",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d903b2c-d617-47f5-ac49-e4d7554824ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "image",
      "text": "Biological diagram of EGFR receptor with mutations",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec2ae59e-b514-4ec4-8deb-5887b83869ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "list",
      "text": "ERAS-801: Higher CNS penetration; Broad activity against oncogenic and wildtype EGFR; Potential as monotherapy; FDA Orphan Drug and Fast Track Designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf701e19-fc84-412d-a3e1-a8c2e3fa780f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "Incidence: ~37,000 patients diagnosed with glioblastoma in the US and Europe annually",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1ae5983-8990-4afc-a733-d51b939249f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.35
      },
      "kind": "list",
      "text": "Standard-of-Care: SOC for rGBM is chemotherapy (3-9% ORR); No EGFR inhibitors approved; Minimal activity against GBM-specific EGFR alterations and poor CNS penetration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f66e8fa3-6ab0-438e-ad71-eafabcbab8f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "THUNDERBBOLT-1: ERAS-801 (CNS-penetrant EGFRi) designed to overcome the limitations of current GBM treatments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d7f632a-2aa8-482a-9428-b306cbd797df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c74f1a8c-c90a-489c-87c3-4e5623923fbe",
      "evidence": "The slide agitates the problem of current GBM treatments and presents ERAS-801 as a potential solution.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "Describing the potential benefits of Erasca's pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}